Wall Street Zen Upgrades Indivior (NASDAQ:INDV) to Strong-Buy

Indivior (NASDAQ:INDV - Get Free Report) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research note issued to investors on Saturday.

Separately, Piper Sandler reduced their price objective on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research note on Thursday, March 6th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Indivior has an average rating of "Buy" and an average target price of $15.00.

Indivior Price Performance

Shares of NASDAQ INDV opened at $14.01 on Friday. Indivior has a 1 year low of $7.33 and a 1 year high of $16.98. The stock has a market cap of $1.92 billion, a P/E ratio of -45.19 and a beta of 0.66. The firm has a 50-day moving average of $11.67 and a 200 day moving average of $11.04.

Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.19. The business had revenue of $266.00 million during the quarter, compared to analyst estimates of $240.13 million. Indivior had a negative net margin of 4.02% and a negative return on equity of 97.29%. Research analysts expect that Indivior will post 1.22 earnings per share for the current fiscal year.

Institutional Trading of Indivior

A number of large investors have recently made changes to their positions in INDV. VELA Investment Management LLC grew its stake in shares of Indivior by 45.5% in the fourth quarter. VELA Investment Management LLC now owns 179,659 shares of the company's stock worth $2,264,000 after acquiring an additional 56,224 shares during the period. Clark Estates Inc. NY grew its stake in shares of Indivior by 1.3% in the fourth quarter. Clark Estates Inc. NY now owns 257,400 shares of the company's stock worth $3,199,000 after acquiring an additional 3,300 shares during the period. Amundi grew its stake in shares of Indivior by 12.2% in the fourth quarter. Amundi now owns 174,434 shares of the company's stock worth $2,109,000 after acquiring an additional 19,010 shares during the period. Kazazian Asset Management LLC purchased a new position in shares of Indivior in the fourth quarter worth approximately $1,706,000. Finally, Landscape Capital Management L.L.C. purchased a new position in shares of Indivior in the fourth quarter worth approximately $978,000. 60.33% of the stock is currently owned by institutional investors.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.